Diphenidine
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Diphenidine is a synthetic dissociative of the diarylethylamine class. It is closely related to phencyclidine and ketamine, but binds their shared target with greater potency. It blocks glutamate signaling in the brain,[1] cutting off normal nerve communication and producing a state of deep disconnection.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
ketamine, phencyclidine, methoxetamine +2 moreketamine, phencyclidine, methoxetamine, methoxphenidine, dextromethorphan show less
First synthesized in 1924,[2] diphenidine was ignored by pharmacologists for nearly nine decades. It resurfaced in 2013 as a research chemical sold online as a legal substitute for ketamine,[3][4] spreading rapidly before hospitalizations and fatalities prompted international action. The United Nations placed it on Schedule II in April 2021.[5]
Subjective effects include deep disconnection from surroundings, hallucinations, depersonalization, euphoria, and profound memory loss. The experience is heavier and more enveloping than ketamine — a dense dissociative fog in which memories of what happened frequently fail to form.[6] Severe agitation, confusion, and paranoia are characteristic unwanted effects.[7][5]
Diphenidine triggers dopamine release in the brain's reward circuits,[8] signaling abuse liability; no human dependence cases have been published.[9] The dominant acute risks are cardiovascular stress and severe agitation; 48 deaths are on record worldwide, most involving multiple substances.[9] No controlled human studies have been conducted; the evidence rests on case reports, animal data, and one comprehensive binding study.[1]
History[edit]
Discovery
Diphenidine was first synthesized in 1924 by Christiaen using a Bruylants reaction[2] — the same chemistry that later yielded phencyclidine. It sat unexamined for roughly 65 years. Related structures were patented as NMDA antagonists for neuroprotection in 1989,[10] but diphenidine itself was never developed clinically.
Research chemical emergence
Diphenidine appeared on UK internet markets in 2013, sold as a legal alternative to ketamine as regulators moved against methoxetamine.[3][4] It was detected in Japan[11] and on Canadian vendor sites[12] in 2014. The first scientific characterization was published in 2015,[13] with comprehensive binding data across 46 receptor sites following in 2016.[1]
Scheduling
Hospitalizations and deaths accumulated rapidly.[7][14] Canada scheduled diphenidine in 2016[12] and the UK banned all novel psychoactive substances the same year.[15] The UN placed it on Schedule II in April 2021,[5] and the UK Advisory Council recommended Class B control in May 2023.[9]
The name diphenidine derives from its two phenyl groups and piperidine ring. It belongs to a structural family alongside pharmaceutical agents — lefetamine, lanicemine, and remacemide — none of which achieved clinical use.[1][4] A 2025 crystallography paper incorrectly dates diphenidine to 2013, reflecting how completely its 1924 synthesis was forgotten.[16]
Chemistry[edit]
Structural class
Diphenidine belongs to the 1,2-diarylethylamine class — two aromatic rings connected through a short carbon bridge.[1][4] This scaffold shares a synthetic lineage with phencyclidine and ketamine through the Bruylants reaction.[2] Its molecular formula is C₁₉H₂₃N (molecular weight 265.4 g/mol).
Molecular structure
| Molecular formula | C₁₉H₂₃N |
| Molecular weight | 265.4 g/mol |
Pharmacology[edit]
Mechanism of action
Diphenidine blocks glutamate signaling by entering open ion channels in the brain and stopping calcium flow.[1][13] This is the same mechanism as phencyclidine and ketamine, producing the same category of dissociative effects. Diphenidine binds this target with substantially greater affinity than ketamine.[1]
It also weakly slows dopamine recycling and, unlike structurally related compounds, increases dopamine release in the brain's reward hub.[8] Methoxphenidine does not share this property.[8] This distinction suggests diphenidine carries greater reinforcement potential than its close structural analog.
Pharmacokinetics
No controlled human pharmacokinetic studies have been conducted. The liver breaks diphenidine down through several pathways involving multiple enzymes.[3] The only human blood concentration on record comes from a single non-fatal poisoning in Italy: 308 ng/mL in plasma and 631 ng/mL in urine.[6]
Neuroscience[edit]
Where it acts
No direct brain imaging studies have been conducted with diphenidine. Based on ketamine research, blocking glutamate signaling disrupts communication between brain regions — raising cortical excitability while reducing normal sensory filtering.[7] The result is sensory input cut off from normal processing: the neurological core of the dissociative state. Dopamine release in reward circuits[8] may drive the euphoria some experience.[6]
Why it matters
When glutamate signaling is blocked, inhibitory brain cells stop functioning normally, and excitatory activity escalates. This generates hallucinations, paranoid thinking, and disorganized perception.[1][5] Diphenidine's clinical presentations fit this pattern closely.
Whether diphenidine's two molecular forms differ in brain effects has never been tested.[17] Its dopamine-releasing properties suggest abuse liability,[8] but no human dependence cases have confirmed or denied this.[9]
Subjective Effects[edit]
Diphenidine pulls awareness into a dense, enveloping dissociative fog. Thought, sensation, and memory lose their normal coherence.[6] It is defined less by what it adds to experience and more by what it removes.
Compared to ketamine, diphenidine occupies similar territory but with a heavier, more amnestic character.[7][1] Ketamine allows a degree of conscious observation from within the dissociated state. Diphenidine tends to swallow that perspective entirely.
Effect Grid
At common doses (75–120 mg oral), the full dissociative experience manifests. Pronounced detachment from body and environment occurs alongside perceptual distortions — spatial warping, altered sound processing, and visual field changes. Hallucinations may emerge, ranging from abstract patterning to more complex scenes. Depersonalization and derealization become prominent. Anterograde amnesia for portions of the experience is common.
Cardiovascular effects are significant at this range: hypertension and tachycardia were documented in 76% and 47% of hospitalized cases, respectively. Physical coordination is substantially impaired; walking becomes difficult or impossible.
The experience demands 3–5 hours of committed time with no obligations. Sleep is typically difficult until effects fully resolve.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Proprioceptive distortion · Vestibular distortion · Visual haze / noise · Ganzfeld effect · Auditory distortion · Peripheral vision distortion · Tracers · Visual drifting · Music enhancement · Auditory suppression · Auditory misinterpretation · Brightness alteration · Color alteration · Dreaming enhancement · Auditory enhancement · Visual morphing · Visual processing suppression · Internal hallucinations · Auditory hallucinations · Environmental orbism / cubism · Visual scenery slicing · External hallucinations
Ganzfeld effect · Auditory distortion · Peripheral vision distortion · Tracers · Visual drifting · Music enhancement · Auditory suppression · Auditory misinterpretation · Brightness alteration · Color alteration · Dreaming enhancement · Auditory enhancement · Visual morphing · Visual processing suppression · Internal hallucinations · Auditory hallucinations · Environmental orbism / cubism · Visual scenery slicing · External hallucinations
Nystagmus (eye wobbles) · Spontaneous body sensations · Body high · Muscle relaxation · Pain suppression · Sedation · Bodily lightness · Nausea · Dry mouth · Laughter fits · Physical fatigue · Pupil dilation · Wakefulness · Salivation · Sexual arousal suppression · Sexual arousal enhancement · Headache · Insomnia · Restlessness · Abnormal heartbeat · Vasoconstriction · Vomiting · Bodily dissociation
Muscle relaxation · Pain suppression · Sedation · Bodily lightness · Nausea · Dry mouth · Laughter fits · Physical fatigue · Pupil dilation · Wakefulness · Salivation · Sexual arousal suppression · Sexual arousal enhancement · Headache · Insomnia · Restlessness · Vasoconstriction · Vomiting · Bodily dissociation
Confusion · Focus suppression · Information processing suppression · Thought disorganization · Pattern recognition suppression · Cognitive euphoria · Thought deceleration · Memory fragmentation · Introspection enhancement · Cognitive fatigue · Language suppression · Suggestibility enhancement · Humor enhancement · Conceptual thinking · Delusions of sobriety · Thought loops · Creativity enhancement · Amnesia · Delirium
Thought disorganization · Pattern recognition suppression · Cognitive euphoria · Thought deceleration · Memory fragmentation · Introspection enhancement · Cognitive fatigue · Language suppression · Humor enhancement · Conceptual thinking · Delusions of sobriety · Thought loops · Creativity enhancement · Amnesia · Delirium
Emotional lability · Dysphoria
Social disconnection · Craving · Sociability suppression · Ego inflation · Sociability enhancement · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Sociability enhancement · Cognitive disconnection · Boundary dissolution · Ego dissolution · Identity alteration
Timeline
First alerts emerge 15–30 minutes after ingestion: a subtle cognitive slowing and mild sense of detachment. Physical effects are minimal at this stage.
Dissociative effects build progressively over 15–30 minutes. Perceptual distortions develop — altered sound processing, spatial warping, and increasing detachment from the body. Heart rate and blood pressure begin to rise.
Maximum dissociation sustained for 1–2 hours. Hallucinations, depersonalization, and anterograde amnesia are most prominent. Motor coordination is severely impaired.
Intensity diminishes but dissociative effects persist at a reduced level for 30–60 minutes. Cognitive function begins to return, though confusion and disorientation may linger. Motor impairment gradually improves.
Effects progressively fade over 30–60 minutes. Residual confusion, difficulty concentrating, and mild perceptual oddities persist. Physical coordination recovers but remains below baseline.
Residual cognitive effects — mild dissociation, fatigue, difficulty concentrating, and mood changes — may persist for 4–24 hours. Sleep quality may be impaired. Memory of the peak experience may be fragmentary or absent.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- Low
- Compulsive redosing
- Moderate
- Dose escalation
- Low
- Cross-tol.
- ketamine · phencyclidine · methoxetamine
Toxicity
No lethal dose has been established for diphenidine in any species. The exact toxic dose in humans is unknown.safety citation needed
Acute toxicity
In hospitalized cases, 76% had elevated blood pressure, 47% had a racing heart, and 65% had altered mental status.[7] Nearly half were severely intoxicated; half required sedation with benzodiazepines or propofol. Median hospital stay was 2 days.
A separate Italian case showed constricted pupils, raised body temperature, and rapid breathing, though other drugs were also present.[6]
Organ damage
Muscle breakdown and acute kidney injury have been reported in diphenidine intoxications.[9] No bladder damage has been documented — unlike with chronic ketamine use. The ACMD notes this absence may reflect fewer chronic users rather than genuine safety.[9]
Deaths
As of the 2023 ACMD review, 48 deaths involving diphenidine have been identified worldwide, with 37 in the UK (primarily 2014–2016).[9] Only 14 were attributed solely to diphenidine or methoxphenidine; the majority involved multiple substances. A fatal case in Japan mapped tissue distribution post-mortem,[14][18] and three deaths attributed primarily to methoxphenidine also showed diphenidine in post-mortem blood.[19]
Psychological Risks
Acute psychological disturbance is a defining feature of diphenidine intoxication. Clinical presentations include severe agitation, confusion, hallucinations, delusions, paranoia, inability to communicate, and memory blackouts.[7][6][5]
As a potent glutamate blocker, diphenidine can trigger or worsen psychotic episodes in vulnerable individuals. No prospective data on psychiatric outcomes following diphenidine exposure have been published, and no diphenidine-specific data exist on persisting perceptual disturbances.
Tolerance & Dependence
No animal studies or human reports of diphenidine dependence or withdrawal have been documented.[9] One case of withdrawal from the related compound methoxphenidine suggests the class may carry withdrawal potential.[9]
Diphenidine increases dopamine release in reward circuits[8] — a property absent in Methoxphenidine that signals greater abuse liability. Community estimates of a 5-day tolerance half-life and 1.5-week full reset are unconfirmed by any published source.safety citation needed
Drug Interactions
No controlled interaction studies have been published for diphenidine. All data derive from co-exposure in clinical case reports.
Depressant combinations
Combining diphenidine with opioids, benzodiazepines, or alcohol compounds sedation and suppresses breathing. Designer benzodiazepines and alcohol have been co-detected in clinical cases.[6][7]
Stimulant combinations
Diphenidine alone raises blood pressure in 76% of hospitalized cases. Adding stimulants compounds this — blood pressure and heart rate rise together in an additive or synergistic way. Amphetamine, MDMA, methylphenidate, and α-PVP have been co-detected in cases.[7]
Serotonergic combinations
Diphenidine has negligible serotonin activity itself,[1] so serotonin syndrome from the compound alone is unlikely. Combinations with MAOIs, SSRIs, or MDMA have not been formally evaluated; indirect effects through glutamate-serotonin signaling cannot be ruled out.
Metabolic interactions
Diphenidine is processed by multiple liver enzymes.[3] Drugs that inhibit those enzymes could raise diphenidine blood levels and extend its effects. Whether diphenidine alters the metabolism of other drugs is unknown.
Contraindications
Heart conditions
Pre-existing high blood pressure, irregular heartbeat, or structural heart disease are relative contraindications. Blood pressure elevation occurred in 76% of hospitalized cases and rapid heartbeat in 47%.[7]
Psychiatric vulnerability
Personal or family history of psychotic disorders is a relative contraindication. Diphenidine produces hallucinations, delusions, and paranoia[5] and can trigger or worsen psychotic episodes.[1]
Kidney impairment
Acute kidney injury has been documented in diphenidine intoxications.[9] Pre-existing kidney impairment increases risk and could prolong exposure to active metabolites.
Liver impairment
Diphenidine is extensively processed by the liver.[3] Impaired liver function could reduce clearance and increase the drug's concentration in the body.
Pregnancy
No reproductive toxicity data exist for diphenidine. NMDA signaling is critical for fetal brain development; class-level animal evidence contraindicates NMDA antagonist exposure during pregnancy.safety citation needed
Harm Reduction[edit]
Forms & Identification
No published physical characterization data exist for diphenidine, making visual identification alone unreliable. Reagent testing is essential for distinguishing it from other dissociatives or adulterants. Market products have been found blended with synthetic cannabinoids[11] — test every batch independently.
Without knowing purity, precise dosing is difficult. A milligram-precision scale and conservative initial doses are baseline precautions.
Guidelines
- Start with the lowest effective dose and wait at least 90 minutes before considering redosing — onset can be slow and unpredictable
- Use a milligram-precision scale; estimating doses of an active powder is dangerous
- Have a sober sitter present who understands dissociative states
- Avoid combining with other substances, particularly depressants and stimulants
- Stay hydrated but avoid alcohol
- Remove hazards from the environment — sharp objects, stairs, open water
- Avoid driving or operating machinery for at least 8 hours following use
- If smoking or vaporizing, be aware that onset is near-instantaneous and far more disorienting than oral use
Set & Setting
Diphenidine's prominent amnestic effects and potential for severe agitation make environment particularly important. A calm, familiar space with minimal stimulation reduces the likelihood of panic or confusion.
A sober, trusted sitter is strongly recommended. Memory blackouts and inability to communicate are documented in clinical cases[6] — the user may be unable to recognize danger or request help.
Aftercare & integration. The prominent amnesia associated with diphenidine means post-experience processing may be fragmentary. Allow at least 24 hours of rest before returning to demanding activities. Sleep, food, and water support physical recovery.
Because memory is often incomplete, a sitter's account of what happened can fill important gaps. Seek professional support if residual confusion, anxiety, or perceptual disturbance persists beyond 48 hours.
Recovery & Support
No published cases of diphenidine dependence exist, but its dopamine-releasing properties provide a mechanistic basis for habit formation.[8] If use becomes compulsive or difficult to stop, the same resources that support dissociative and stimulant misuse apply: professional addiction counseling, peer support, and harm reduction services.
Escalating frequency, using alone, and difficulty controlling dose are early warning signs — regardless of whether formal dependence criteria are met.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Unresponsiveness, seizure, chest pain, extremely high body temperature, or complete inability to communicate beyond what is expected from dissociation. Severe agitation where the person is a danger to themselves or others. Blue or grey skin coloring.
Immediate steps:
- Call emergency services immediately if the person is unconscious, seizing, or showing signs of cardiovascular distress
- Place an unconscious but breathing person in the recovery position
- Do not restrain an agitated person unless there is immediate danger of self-harm — restraint can worsen agitation and raise body temperature
- Keep the environment quiet and low-stimulation
- Monitor breathing and pulse while waiting for help
What to tell the dispatcher: Name the substance (diphenidine, a dissociative), approximate amount taken if known, time of ingestion, current symptoms, and any other substances consumed. Good Samaritan laws in many jurisdictions protect callers who report drug emergencies.
Legal Status[edit]
Diphenidine is controlled internationally under Schedule II of the Convention on Psychotropic Substances 1971, adopted in April 2021 on the recommendation of the WHO Expert Committee.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| International | Schedule II (Convention on Psychotropic Substances 1971) | 64th CND, April 2021; implementing 43rd ECDD recommendation[5] |
| United States | Not scheduled (CSA) | Subject to international Schedule II obligations; Federal Analogue Act may apply if intended for human consumption. No domestic scheduling rule confirmed as of May 2026 |
| United Kingdom | Psychoactive Substances Act 2016 (blanket ban); Class B MDA 1971 recommended | ACMD recommended Class B, Schedule 1 under Misuse of Drugs Act 1971 on 26 May 2023;[9] legislative implementation status pending at time of writing |
| Canada | Schedule I (CDSA) | Listed as DEP, classified as analogue of MT-45; effective November 2016[12] |
| Germany | Controlled substance | Production and sale illegal; possession for personal use not penalizedcitation needed |
| Australia | Controlled substance | Listed on Office of Drug Control controlled substances registercitation needed |
| Sweden | Controlled under NPS legislation | Monitored through the STRIDA clinical-toxicological surveillance project[7] |
Legal status changes frequently and varies by jurisdiction. This information reflects available records as of May 2026 and is not legal advice. Verify current laws in any relevant jurisdiction before relying on this information.
references
- [1]
- [2]
- [3]
- [4] ^abcdWallach J, Brandt SD (2018) 1,2-Diarylethylamine- and Ketamine-Based New Psychoactive Substances — Handbook of Experimental Pharmacology doi:10.1007/164_2018_148
- [5]
- [6]